{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:26:33Z","timestamp":1770992793941,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T00:00:00Z","timestamp":1519171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["J3-4259"],"award-info":[{"award-number":["J3-4259"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00262-018-2133-0","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T17:20:45Z","timestamp":1519233645000},"page":"785-795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Antitumor in situ vaccination effect of TNF\u03b1 and IL-12 plasmid DNA electrotransfer in a murine melanoma model"],"prefix":"10.1007","volume":"67","author":[{"given":"Urska","family":"Kamensek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Cemazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursa","family":"Lampreht Tratar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Ursic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Sersa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,21]]},"reference":[{"key":"2133_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-bioeng-071813-104622","volume":"16","author":"ML Yarmush","year":"2014","unstructured":"Yarmush ML, Golberg A, Sersa G et al (2014) Electroporation-based technologies for medicine: principles, applications, and challenges. Annu Rev Biomed Eng 16:295\u2013320. \n                    https:\/\/doi.org\/10.1146\/annurev-bioeng-071813-104622","journal-title":"Annu Rev Biomed Eng"},{"key":"2133_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2174\/156652310791823425","volume":"10","author":"M Cemazar","year":"2010","unstructured":"Cemazar M, Jarm T, Sersa G (2010) Cancer electrogene therapy with interleukin-12. Curr Gene Ther 10:300\u2013311","journal-title":"Curr Gene Ther"},{"key":"2133_CR3","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1200\/JCO.2007.15.6794","volume":"26","author":"AI Daud","year":"2008","unstructured":"Daud AI, DeConti RC, Andrews S et al (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26:5896\u20135903. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.15.6794","journal-title":"J Clin Oncol"},{"issue":"2","key":"2133_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/QAI.0000000000000830","volume":"71","author":"JM Jacobson","year":"2016","unstructured":"Jacobson JM, Zheng L, Wilson CC et al (2016) The safety and immunogenicity of an interleukin-12-enhanced multiantigen DNA vaccine delivered by electroporation for the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 71(2):163\u2013171. \n                    https:\/\/doi.org\/10.1097\/QAI.0000000000000830","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2133_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.plasmid.2016.11.004","volume":"89","author":"U Kamensek","year":"2017","unstructured":"Kamensek U, Tesic N, Sersa G et al (2017) Plasmid tailor-made fibroblast-specific and antibiotic-free interleukin 12 plasmid for gene electrotransfer-mediated cancer immunotherapy. Plasmid 89:9\u201315. \n                    https:\/\/doi.org\/10.1016\/j.plasmid.2016.11.004","journal-title":"Plasmid"},{"key":"2133_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","volume":"63","author":"W Lasek","year":"2014","unstructured":"Lasek W, Zagozdzon R, Jakobisiak M (2014) Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 63:419\u2013435. \n                    https:\/\/doi.org\/10.1007\/s00262-014-1523-1","journal-title":"Cancer Immunol Immunother"},{"key":"2133_CR7","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1016\/j.vaccine.2006.11.070","volume":"25","author":"SY Chong","year":"2007","unstructured":"Chong SY, Egan MA, Kutzler MA et al (2007) Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV89.6P challenge in rhesus macaques. Vaccine 25:4967\u20134982. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2006.11.070","journal-title":"Vaccine"},{"key":"2133_CR8","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1080\/21645515.2015.1049779","volume":"11","author":"RH Pierce","year":"2015","unstructured":"Pierce RH, Campbell JS, Pai SI et al (2015) In-situ tumor vaccination: bringing the fight to the tumor. Hum Vaccines Immunother 11:1901\u20131909. \n                    https:\/\/doi.org\/10.1080\/21645515.2015.1049779","journal-title":"Hum Vaccines Immunother"},{"key":"2133_CR9","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00262-015-1724-2","volume":"64","author":"G Sersa","year":"2015","unstructured":"Sersa G, Teissie J, Cemazar M et al (2015) Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 64:1315\u20131327. \n                    https:\/\/doi.org\/10.1007\/s00262-015-1724-2","journal-title":"Cancer Immunol Immunother"},{"key":"2133_CR10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00262-017-2000-4","volume":"66","author":"G Deplanque","year":"2017","unstructured":"Deplanque G, Shabafrouz K, Obeid M (2017) Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow \u201cin situ tumor vaccination\u201d? Cancer Immunol Immunother 66:833\u2013840. \n                    https:\/\/doi.org\/10.1007\/s00262-017-2000-4","journal-title":"Cancer Immunol Immunother"},{"key":"2133_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fimmu.2017.00229","volume":"8","author":"E Wennerberg","year":"2017","unstructured":"Wennerberg E, Lhuillier C, Vanpouille-Box C et al (2017) Barriers to radiation-induced in situ tumor vaccination. Front Immunol 8:229. \n                    https:\/\/doi.org\/10.3389\/fimmu.2017.00229","journal-title":"Front Immunol"},{"key":"2133_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1634\/theoncologist.11-4-397","volume":"11","author":"R Horssen van","year":"2006","unstructured":"van Horssen R, Ten Hagen TLM, Eggermont AMM (2006) TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11:397\u2013408. \n                    https:\/\/doi.org\/10.1634\/theoncologist.11-4-397","journal-title":"Oncologist"},{"key":"2133_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s002620050408","volume":"45","author":"W Lasek","year":"1997","unstructured":"Lasek W, Feleszko W, Golab J et al (1997) Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor alpha in mice. Cancer Immunol Immunother 45:100\u2013108. \n                    https:\/\/doi.org\/10.1016\/s0165-2478(97)88205-3","journal-title":"Cancer Immunol Immunother"},{"key":"2133_CR14","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/bjc.2015.246","volume":"113","author":"LE Podleska","year":"2015","unstructured":"Podleska LE, Funk K, Umutlu L et al (2015) TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature. Br J Cancer 113:645\u2013652. \n                    https:\/\/doi.org\/10.1038\/bjc.2015.246","journal-title":"Br J Cancer"},{"issue":"7","key":"2133_CR15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1200\/JCO.2012.44.7516","volume":"31","author":"JM Herman","year":"2013","unstructured":"Herman JM, Wild AT, Wang H et al (2013) Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol 31(7):886\u2013894. \n                    https:\/\/doi.org\/10.1200\/Jco.2012.44.7516","journal-title":"J Clin Oncol"},{"key":"2133_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1517\/14712598.2010.482925","volume":"10","author":"J Hernandez","year":"2010","unstructured":"Hernandez J, Cooper J, Babel N et al (2010) TNFalpha gene delivery therapy for solid tumors. Expert Opin Biol Ther 10:993\u2013999. \n                    https:\/\/doi.org\/10.1517\/14712598.2010.482925","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"2133_CR17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/gt.2015.26","volume":"22","author":"M Bosnjak","year":"2015","unstructured":"Bosnjak M, Dolinsek T, Cemazar M et al (2015) Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma. Gene Ther 22(7):578\u2013590. \n                    https:\/\/doi.org\/10.1038\/gt.2015.26","journal-title":"Gene Ther"},{"key":"2133_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1515\/raon-2017-0011","volume":"51","author":"M Savarin","year":"2017","unstructured":"Savarin M, Kamensek U, Cemazar M et al (2017) Electrotransfer of plasmid DNA radiosensitizes B16F10 tumors through activation of immune response. Radiol Oncol 51:30\u201339. \n                    https:\/\/doi.org\/10.1515\/raon-2017-0011","journal-title":"Radiol Oncol"},{"key":"2133_CR19","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1038\/mtna.2016.4","volume":"5","author":"LL Lesueur","year":"2016","unstructured":"Lesueur LL, Mir LM, Andr\u00e9 FM (2016) Overcoming the specific toxicity of large plasmids electrotransfer in primary cells in vitro. Mol Ther Nucleic Acids 5:e291. \n                    https:\/\/doi.org\/10.1038\/mtna.2016.4","journal-title":"Mol Ther Nucleic Acids"},{"key":"2133_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1534\/genetics.115.176594","volume":"200","author":"W Qin","year":"2015","unstructured":"Qin W, Dion SL, Kutny PM et al (2015) Efficient CRISPR\/Cas9-mediated genome editing in mice by zygote electroporation of nuclease. Genetics 200:423\u2013430. \n                    https:\/\/doi.org\/10.1534\/genetics.115.176594","journal-title":"Genetics"},{"key":"2133_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.yexcr.2015.08.004","volume":"338","author":"J Liu","year":"2015","unstructured":"Liu J, Brzeszczynska J, Samuel K et al (2015) Efficient episomal reprogramming of blood mononuclear cells and differentiation to hepatocytes with functional drug metabolism. Exp Cell Res 338:203\u2013213. \n                    https:\/\/doi.org\/10.1016\/j.yexcr.2015.08.004","journal-title":"Exp Cell Res"},{"issue":"9","key":"2133_CR22","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/mt.2016.122","volume":"24","author":"L Lambricht","year":"2016","unstructured":"Lambricht L, Vanvarenberg K, De Beuckelaer A et al (2016) Coadministration of a plasmid encoding HIV-1 Gag enhances the efficacy of cancer DNA vaccines. Mol Ther 24(9):1686\u20131696. \n                    https:\/\/doi.org\/10.1038\/mt.2016.122","journal-title":"Mol Ther"},{"key":"2133_CR23","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1002\/ijc.22100","volume":"119","author":"J Liu","year":"2006","unstructured":"Liu J, Xia X, Torrero M, Barrett R, Shillitoe EJ, Li S (2006) The mechanism of exogenous B7.1-enhanced IL-12-mediated complete regression of tumors by a single electroporation delivery. Int J Cancer 119:2113\u20132118. \n                    https:\/\/doi.org\/10.1002\/ijc.22100","journal-title":"Int J Cancer"},{"key":"2133_CR24","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/ijms11030789","volume":"11","author":"T Hamza","year":"2010","unstructured":"Hamza T, Barnett JB, Li B (2010) Interleukin 12 a key immunoregulatory cytokine in infection applications. Int J Mol Sci 11:789\u2013806. \n                    https:\/\/doi.org\/10.3390\/ijms11030789","journal-title":"Int J Mol Sci"},{"key":"2133_CR25","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.ymthe.2004.07.028","volume":"10","author":"T Goto","year":"2004","unstructured":"Goto T, Nishi T, Kobayashi O, Tamura T, Dev SB, Takeshima H, Kochi M, Kuratsu JI, Sakata T, Ushio Y (2004) Combination electro-gene therapy using herpes virus thymidine kinase and interleukin-12 expression plasmids is highly efficient against murine carcinomas in vivo. Mol Ther 10:929\u2013937. \n                    https:\/\/doi.org\/10.1016\/j.ymthe.2004.07.028","journal-title":"Mol Ther"},{"key":"2133_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/jgm.335","volume":"5","author":"M-A Shibata","year":"2003","unstructured":"Shibata M-A, Horiguchi T, Morimoto J, Otsuki Y (2003) Massive apoptotic cell death in chemically induced rat urinary bladder carcinomas followingin situ HSVtk electrogene transfer. J Gene Med 5:219\u2013231. \n                    https:\/\/doi.org\/10.1002\/jgm.335","journal-title":"J Gene Med"},{"issue":"1","key":"2133_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/sj.cgt.7700415","volume":"9","author":"MA Shibata","year":"2002","unstructured":"Shibata MA, Morimoto J, Otsuki Y (2002) Suppression of murine mammary carcinoma growth and metastasis by HSVtk\/GCV gene therapy using in vivo electroporation. Cancer Gene Ther 9(1):16\u201327. \n                    https:\/\/doi.org\/10.1038\/sj.cgt.7700415","journal-title":"Cancer Gene Ther"},{"key":"2133_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1089\/10430340252769798","volume":"13","author":"Y-I Yamashita","year":"2002","unstructured":"Yamashita Y-I, Shimada M, Tanaka S, Okamamoto M, Miyazaki J-I, Sugimachi K (2002) Electroporation-mediated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)\/Apo2L gene therapy for hepatocellular carcinoma. Hum Gene Ther 13:275\u2013286. \n                    https:\/\/doi.org\/10.1089\/10430340252769798","journal-title":"Hum Gene Ther"},{"issue":"7","key":"2133_CR29","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/cdd.2017.65","volume":"24","author":"S Grootjans","year":"2017","unstructured":"Grootjans S, Vanden Berghe T, Vandenabeele P (2017) Initiation and execution mechanisms of necroptosis: an overview. Cell Death Differ 24(7):1184\u20131195. \n                    https:\/\/doi.org\/10.1038\/cdd.2017.65","journal-title":"Cell Death Differ"},{"issue":"12","key":"2133_CR30","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/eji.200737450","volume":"37","author":"L Mortara","year":"2007","unstructured":"Mortara L, Balza E, Sassi F, Castellani P, Carnemolla B, Barbaro ADL, Fossati S, Tosi G, Accolla RS, Borsi L (2007) Therapy-induced antitumor vaccination by targeting tumor necrosis factor- a to tumor vessels in combination with melphalan. Eur J Immunol 37(12):3381\u20133392. \n                    https:\/\/doi.org\/10.1002\/eji.200737450.3381-3392","journal-title":"Eur J Immunol"},{"issue":"35","key":"2133_CR31","doi-asserted-by":"publisher","first-page":"57391","DOI":"10.18632\/oncotarget.10548","volume":"7","author":"M Meng","year":"2016","unstructured":"Meng M, Wang H, Cui Y, Wu Z, Shi Y-Y, Zaorsky NG, Deng L, Yuan Z-Y, Lu Y, Wang P (2016) Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy. Oncotarget 7(35):57391\u201357413. \n                    https:\/\/doi.org\/10.18632\/oncotarget.10548","journal-title":"Oncotarget"},{"key":"2133_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00262-016-1914-6","volume":"66","author":"D Ishihara","year":"2017","unstructured":"Ishihara D, Pop L, Takeshima T, Iyengar P, Hannan R (2017) Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment. Cancer Immunol Immunother 66:281\u2013298. \n                    https:\/\/doi.org\/10.1007\/s00262-016-1914-6","journal-title":"Cancer Immunol Immunother"},{"key":"2133_CR33","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan JD, Kitano S, Mu ZY, Rasalan T, Adamow M, Ritter E et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925\u2013931. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1112824","journal-title":"N Engl J Med"},{"key":"2133_CR34","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1158\/0008-5472.CAN-11-1316","volume":"71","author":"WH Fridman","year":"2011","unstructured":"Fridman WH, Galon J, Pag\u00e8s F, Tartour E, Saut\u00e8s-Fridman C, Kroemer G (2011) Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 71:5601\u20135605. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1316","journal-title":"Cancer Res"},{"key":"2133_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.4287","volume":"232","author":"J Galon","year":"2014","unstructured":"Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C et al (2014) Towards the introduction of the \u201cImmunoscore\u201d in the classification of malignant tumours. J Pathol 232:199\u2013209. \n                    https:\/\/doi.org\/10.1002\/path.4287","journal-title":"J Pathol"},{"key":"2133_CR36","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40425-017-0243-4","volume":"5","author":"S Gnjatic","year":"2017","unstructured":"Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN et al (2017) Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer 5:44. \n                    https:\/\/doi.org\/10.1186\/s40425-017-0243-4","journal-title":"J Immunother Cancer"},{"key":"2133_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/cdd.2014.134","volume":"22","author":"S Tugues","year":"2015","unstructured":"Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B (2015) New insights into IL-12-mediated tumor suppression. Cell Death Differ 22:237\u2013246. \n                    https:\/\/doi.org\/10.1038\/cdd.2014.134","journal-title":"Cell Death Differ"},{"key":"2133_CR38","doi-asserted-by":"publisher","first-page":"5285890","DOI":"10.1155\/2017\/5285890","volume":"2017","author":"U Lampreht Tratar","year":"2017","unstructured":"Lampreht Tratar U, Loiacono L, Cemazar M, Kamensek U, Fazio VM, Sersa G, Signori E (2017) Gene electrotransfer of plasmid-encoding IL-12 recruits the M1 macrophages and antigen-presenting cells inducing the eradication of aggressive B16F10 murine melanoma. Mediat Inflamm 2017:5285890. \n                    https:\/\/doi.org\/10.1155\/2017\/5285890","journal-title":"Mediat Inflamm"},{"key":"2133_CR39","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1006\/mthe.2002.0601","volume":"5","author":"ML Lucas","year":"2002","unstructured":"Lucas ML, Heller L, Coppola D, Heller R (2002) IL-12 Plasmid delivery by in vivo electroporation for B16-F10 melanoma. Mol Ther 5:668\u2013675. \n                    https:\/\/doi.org\/10.1006\/mthe.2002.0601","journal-title":"Mol Ther"},{"key":"2133_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2174\/1566523216666160331125611","volume":"16","author":"U Kamensek","year":"2016","unstructured":"Kamensek U, Rols M-P, Cemazar M, Golzio M (2016) Visualization of nonspecific antitumor effectiveness and vascular effects of gene electro-transfer to tumors. Curr Gene Ther 16:90\u201397. \n                    https:\/\/doi.org\/10.2174\/1566523216666160331125611","journal-title":"Curr Gene Ther"},{"key":"2133_CR41","doi-asserted-by":"publisher","first-page":"e28540","DOI":"10.4161\/onci.28540","volume":"3","author":"CY Calvet","year":"2014","unstructured":"Calvet CY, Andre FM, Mir LM (2014) Dual therapeutic benefit of electroporation-mediated DNA vaccination in vivo Enhanced gene transfer and adjuvant activity. Oncoimmunology 3:e28540. \n                    https:\/\/doi.org\/10.4161\/onci.28540","journal-title":"Oncoimmunology"},{"issue":"7","key":"2133_CR42","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"H Teulings","year":"2015","unstructured":"Teulings H, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33(7):773\u2013781. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.57.4756","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2133-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2133-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2133-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T20:14:28Z","timestamp":1550693668000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2133-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,21]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2133"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2133-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,21]]},"assertion":[{"value":"23 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments were performed in accordance with the official guidelines of EU Directive 2010\/63\/EU, and with permission from the Veterinary Administration of the Ministry of Agriculture, Forestry and Food of the Republic of Slovenia (permission no. 34401-4\/2012\/4, 34401-1\/2015\/7). Mice were housed in a specific pathogen-free colony at a constant room temperature with a 12\u00a0h light\/dark cycle, and provided with food and water ad libitum. Prior to any experiments, mice were subjected to a quarantine period of 2 weeks.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and ethical standards"}},{"value":"Six-to-eight-week-old female C57BL\/6 mice were purchased from Envigo (Udine, Italy).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal source"}},{"value":"The B16F10 murine melanoma cell line was purchased from American-Type Culture Collection, Manassas, VA, USA.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}